In situ cytogenetic morphology and analysis showed that Epstein-Barr Virus (EBV)-infected Raji and EBV-producing P3HR-1 cells divide by meiosis and follow the life cycle of malignant cells in vitro. Meiosis was documented by the presence of condensed chromosomes, "o" chromosome, nuclear vlimata (NVs), NV invasion, extrusion of chromosomes, chromosomal transfer, metaphase fusion and aneuploidy. EBV-Raji, EBV-producing P3HR, HIV1-infected MOLT-4 cells (dividing by meiosis) and human spermatozoa (cellular products of meiosis) were highly sensitive to the endogenous inhibitor (CANP-I) of calcium-activated neutral proteinase (CANP). CANP-I-treated virally infected and virus producing cells showed necrosis and disappearance of immunofluorescent viral antigens, documenting the anti-viral action of CANP-I. CANP-I-treated spermatozoa exhibited arrested motility with subsequent necrosis documenting the in vitro spermicidal action of CANP-I. The testis of treated Wistar rats with 0.25 U CANP-I/gr body weight for six days, were devoid of spermatozoa, with pronounced toxicity and exfoliation of spermatocytes and spermatids, indicating the contraceptive action of CANP-I via spermatogenetic arrest. It is concluded that CANP-I is an anti-meiotic agent inhibiting CANP associated with meiosis. Hence CANP-I is a promising agent against various diseases involving meiosis.
Download full-text PDF |
Source |
---|
ACS Infect Dis
March 2021
Department of Pharmacology and Toxicology, College of Pharmacy, The University of Arizona, Tucson, Arizona 85721, United States.
As the COVID-19 pandemic continues to unfold, the morbidity and mortality are increasing daily. Effective treatment for SARS-CoV-2 is urgently needed. We recently discovered four SARS-CoV-2 main protease (M) inhibitors including boceprevir, calpain inhibitors II and XII, and GC-376 with potent antiviral activity against infectious SARS-CoV-2 in cell culture.
View Article and Find Full Text PDFbioRxiv
November 2020
Department of Pharmacology and toxicology, College of Pharmacy, University of Arizona, 1703 E. Mabel St, Tucson, AZ, 85721, United States.
As the COVID-19 pandemic continues to fold out, the morbidity and mortality are increasing daily. Effective treatment for SARS-CoV-2 is urgently needed. We recently discovered four SARS-CoV-2 main protease (Mpro) inhibitors including boceprevir, calpain inhibitors II and XII and GC-376 with potent antiviral activity against infectious SARS-CoV-2 in cell culture.
View Article and Find Full Text PDFCell Res
August 2020
Department of Pharmacology and Toxicology, College of Pharmacy, The University of Arizona, Tucson, AZ, 85721, USA.
A new coronavirus SARS-CoV-2, also called novel coronavirus 2019 (2019-nCoV), started to circulate among humans around December 2019, and it is now widespread as a global pandemic. The disease caused by SARS-CoV-2 virus is called COVID-19, which is highly contagious and has an overall mortality rate of 6.35% as of May 26, 2020.
View Article and Find Full Text PDFbioRxiv
January 2020
Department of Pharmacology and Toxicology, College of Pharmacy, The University of Arizona, Tucson, AZ, 85721, United States.
A novel coronavirus SARS-CoV-2, also called novel coronavirus 2019 (nCoV-19), started to circulate among humans around December 2019, and it is now widespread as a global pandemic. The disease caused by SARS-CoV-2 virus is called COVID-19, which is highly contagious and has an overall mortality rate of 6.96% as of May 4, 2020.
View Article and Find Full Text PDFCell Microbiol
March 2019
Institute for Experimental and Clinical Pharmacology and Toxicology, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
Photorhabdus luminescens Tc toxins consist of the cell-binding component TcA, the linker component TcB, and the enzyme component TcC. TccC3, a specific isoform of TcC, ADP-ribosylates actin and causes redistribution of the actin cytoskeleton. TccC5, another isoform of TcC, ADP-ribosylates and activates Rho proteins.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!